Woo Raymond sold $132K of CBLL

Woo Raymond (Chief Technology Officer) sold 4,887 shares of Ceribell, Inc. (CBLL) at $26.96 ($0.13M total) on 2026-11-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Woo Raymond
Published Nov 4, 2026, 5:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 5:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CBLL
Bearish
medium confidence
Mentioned
$CBLL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CBLLBearishLow
01

Why it matters

The disclosed sale reduces insider ownership but is small relative to total shares outstanding.

02

Market read

A routine insider sale with modest size; limited trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 3/10Timing: post‑market 2026‑11‑04

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$CBLLBearishMedium confidence
Context

Chief Technology Officer Woo Raymond sold 4,887 shares for $131,753.52 via a 10b5-1 plan, reducing his stake to 203,118 shares.

Expected impact

likely modest pressure as the market prices in the insider sell

Evidence & confidence

The sale is modest in size ($132K) and executed under a pre‑arranged plan, suggesting limited immediate impact but a potential slight downside bias.

Market effects

Minimal effect on the medical‑device sector; insider sales are routine.

No broader regional impact.

Limited to Ceribell shareholders.

Counterpoint

The sale could be unrelated to company fundamentals; price may remain unchanged.

Key entities

  • Ceribell, Inc.

    Medical‑device company listed on NASDAQ under CBLL.

  • Woo Raymond

    Chief Technology Officer of Ceribell.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CBLLMedAI 8/10

CeriBell Inc (CBLL) (Q3 2026) Earnings Call Highlights: Record Hospital Additions

CeriBell Inc (CBLL) reported Q3 2026 revenue of $29.3M, up 30% YoY, with 35 new hospitals added. Gross margin improved to 90%, but net loss widened to $21.4M. Full-year guidance raised to $115-$117M. Delirium monitoring pilot showed clinical impact, but no material revenue contribution yet. Operating expenses rose 36% YoY. CEO Jane Chao and CFO Scott Blomberg discussed growth strategies and 2027 outlook.

$CBLLHigh

Ceribell Reports Third Quarter 2026 Financial Results

Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ceribell Reports Third Quarter 2026 Financial Results Sunnyvale, Calif. – November 3, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repor

$EWHighAI 8/10

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

$CBLLMedAI 8/10

Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis

Ceribell, Inc. (Nasdaq: CBLL) received FDA 510(k) clearance for new software for its EEG system, enabling easier interpretation of brain activity trends. The update includes Alpha-Delta Ratio, Burst Suppression, and Amplitude-Integrated EEG monitoring, applicable to patients of all ages. The company expects to roll out the features in the first half of 2027.